Show simple item record

dc.contributor.authorKeane, Colm
dc.contributor.authorNourse, Jamie P.
dc.contributor.authorCrooks, Pauline
dc.contributor.authorNguyen-Van, Do
dc.contributor.authorMutsando, Howard
dc.contributor.authorMollee, Peter
dc.contributor.authorLea, Rodney
dc.contributor.authorGandhi, Maher K.
dc.date.accessioned2018-01-25T12:30:34Z
dc.date.available2018-01-25T12:30:34Z
dc.date.issued2012
dc.date.modified2013-05-24T02:37:27Z
dc.identifier.issn14440903
dc.identifier.doi10.1111/j.1445-5994.2011.02587.x
dc.identifier.urihttp://hdl.handle.net/10072/50781
dc.description.abstractBackground Recent reports suggest genetic polymorphisms influence susceptibility to rituximab induced late-onset neutropenia (LON), which in turn may be a predictor of good outcome in B-cell lymphoma. Aims We report the largest study to date assessing FCGR3A-V158F polymorphisms in Diffuse Large B-cell Lymphoma (DLBCL) treated with CHOP-R. The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. Methods 115 DLBCL patients treated with CHOP-R were compared with 105 healthy Caucasian controls with regards to FCGR3A-V158F and C1qA-A276G polymorphisms . LON incidence and event free and overall survival (EFS and OS) were analysed for linkage to either polymorphism. Results The FCGR3A-V158F but not the C1qA-A276G polymorphism influenced the risk of developing LON. 50% of FCGR3A-158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A-158V/V genotype was associated with LON compared to V/F (p=0.028) and F/F genotypes (p=0.005). Although no patients with either LON or FCGR3A-158V homozygosity relapsed compared to 33% FCGR3A-158F/F and 21% non-LON, this did not translate into improved EFS or OS. Conclusions Polymorphic analysis may be a predictive tool to identify those at high-risk of LON. Prospective studies are required to definitively establish if LON or FCGR3A-158V/V genotype influences outcome.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.publisherWiley-Blackwell Publishing Asia
dc.publisher.placeAustralia
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom1113
dc.relation.ispartofpageto1119
dc.relation.ispartofissue10
dc.relation.ispartofjournalInternal Medicine Journal
dc.relation.ispartofvolume42
dc.rights.retentionY
dc.subject.fieldofresearchImmunogenetics (incl. Genetic Immunology)
dc.subject.fieldofresearchCardiorespiratory Medicine and Haematology
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode110706
dc.subject.fieldofresearchcode1102
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1117
dc.titleHomozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for Diffuse Large B-cell Lymphoma
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2012 Royal Australasian College of Physicians. This is the peer reviewed version of the following article: Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma, Internal Medicine Journal, Volume 42, Issue 10, Pages 1113–1119, which has been published in final form at 10.1111/j.1445-5994.2011.02587.x. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
gro.date.issued2012
gro.hasfulltextFull Text
gro.griffith.authorLea, Rodney A.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record